Overview

Relative Bioavailability and Food Effect Study of CVN424

Status:
Completed
Trial end date:
2022-11-21
Target enrollment:
Participant gender:
Summary
This is a Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension and Tablet Formulations in Healthy Volunteers Under Fasted and Fed Conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Cerevance Beta, Inc.